VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
Leoni G, D’Alise AM et al. Vaccines 2021
Leoni G, D’Alise AM et al. Vaccines 2021
Leoni G et al, Cancer Research, 2020
Sasso E, D’Alise AM et al. Semin Immunol. 2020
D’Alise AM et al., Nature Comms, 2019
Chang et al., JAMA Oncology, 2018
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.